[{"Assets_0_Q3_USD":1218500000.0,"CommonStockSharesOutstanding_0_Q3_shares":69900000.0,"EarningsPerShareBasic_1_Q3_USD":0.16,"EarningsPerShareBasic_3_Q3_USD":1.8,"EarningsPerShareDiluted_1_Q3_USD":0.16,"EarningsPerShareDiluted_3_Q3_USD":1.74,"NetIncomeLoss_1_Q3_USD":11400000.0,"NetIncomeLoss_3_Q3_USD":124600000.0,"StockholdersEquity_0_Q3_USD":948300000.0,"WeightedAverageNumberOfDilutedSharesOutstanding_1_Q3_shares":72400000.0,"WeightedAverageNumberOfDilutedSharesOutstanding_3_Q3_shares":71700000.0,"WeightedAverageNumberOfSharesOutstandingBasic_1_Q3_shares":69800000.0,"WeightedAverageNumberOfSharesOutstandingBasic_3_Q3_shares":69200000.0,"Ticker":"MYGN","CIK":"899923","name":"MYRIAD GENETICS INC","OfficialName":"Myriad Genetics Inc. Common Stock","form":"10-Q","period":"20180331","fy":"2018.0","fp":"Q3","qtrs":"0","uom":"USD","footnote":"nan","Market Cap":"1850258412.0","Country":"United States","Sector":"Health Care","Industry":"Biotechnology: In Vitro & In Vivo Diagnostic Substances","Market":"NASDAQ","SP500":"nan","filed":"20180509"}]